Cited by 526Chromatin Remodeling and CancerPARP inhibition in cancer therapyDNA Repair Mechanisms

The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.

ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors

Open access

Shen, Jianfeng, Peng, Yang, Wei, Leizhen, Zhang, Wei, Yang, Lin, Lan, Li, Kapoor, Prabodh, Ju, Zhenlin, Mo, Qianxing, Shih, Ie-Ming, Uray, Ivan P., Wu, Xiangwei, Brown, Powel H., Shen, Xuetong, Mills, Gordon B., Peng, Guang·2015·Cancer Discovery

DOI 10.1158/2159-8290.cd-14-0849PMC PMC4497871

Published version of a preprint

Open this paper in CoChat — free account

Abstract

ARID1A, SWI/SNF chromatin remodeling complex subunit, is a recently identified tumor suppressor that is mutated in a broad spectrum of human cancers. Thus, it is of fundamental clinical importance to understand its molecular functions and determine whether ARID1A deficiency can be exploited therapeutically. In this article, we report a key function of ARID1A in regulating the DNA damage checkpoint. ARID1A is recruited to DNA double-strand breaks (DSB) via its interaction with the upstream DNA damage checkpoint kinase ATR. At the molecular level, ARID1A facilitates efficient processing of DSB to single-strand ends and sustains DNA damage signaling. Importantly, ARID1A deficiency sensitizes cancer cells to PARP inhibitors in vitro and in vivo, providing a potential therapeutic strategy for patients with ARID1A-mutant tumors. Significance: ARID1A has been identified as one of the most frequently mutated genes across human cancers. Our data suggest that clinical utility of PARP inhibitors might be extended beyond patients with BRCA mutations to a larger group of patients with ARID1A-mutant tumors, which may exhibit therapeutic vulnerability to PARP inhibitors. Cancer Discov; 5(7); 752–67. ©2015 AACR. This article is highlighted in the In This Issue feature, p. 681

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-14-0849

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cancer Genome Landscapes
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
The DNA-damage response in human biology and disease
Jackson, S. P., & Bartek, J. (2009) · Nature · doi:10.1038/nature08467 · Cited by 6,092
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
The DNA Damage Response: Making It Safe to Play with Knives
Ciccia, A., & Elledge, S. J. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.019 · Cited by 4,368
DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation
Bakkenist, C. J., & Kastan, M. B. (2003) · Nature · doi:10.1038/nature01368 · Cited by 3,466
The DNA damage response: putting checkpoints in perspective
Zhou, B.-B. S., & Elledge, S. J. (2000) · Nature · doi:10.1038/35044005 · Cited by 3,213
Sensing DNA Damage Through ATRIP Recognition of RPA-ssDNA Complexes
Zou, L., & Elledge, S. J. (2003) · Science · doi:10.1126/science.1083430 · Cited by 2,693
Megabase Chromatin Domains Involved in DNA Double-Strand Breaks in Vivo
Rogakou, E. P., Boon, C., Redon, C., & Bonner, W. M. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.146.5.905 · Cited by 2,422
ATR: an essential regulator of genome integrity
Cimprich, K. A., & Cortez, D. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2450 · Cited by 1,798

Flagged first, then by citations

Show all 61 references

Sorted by citations

Items 101–200 of 526

ARID1A and CTNNB1/β-Catenin Molecular Status Affects the Clinicopathologic Features and Prognosis of Endometrial Carcinoma: Implications for an Improved Surrogate Molecular Classification
Leo, A. D., de Biase, D., Lenzi, J., Barbero, G., Turchetti, D., Grillini, M., Ravegnini, G., Angelini, S., Zamagni, C., Coluccelli, S., et al. (2021) · Cancers · doi:10.3390/cancers13050950 · Cited by 56
ARID1A in cancer: Friend or foe?
Fontana, B., Gallerani, G., Salamon, I., Pace, I., Roncarati, R., & Ferracin, M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1136248 · Cited by 58
Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors
Lim, J., & Tan, D. S. P. (2017) · Cancers · doi:10.3390/cancers9080109 · Cited by 52
Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches
Şahin, İ. H., Lowery, M. A., Stadler, Z. K., Salo‐Mullen, E. E., Iacobuzio–Donahue, C. A., Kelsen, D. P., & O'Reilly, E. M. (2016) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2016.1153424 · Cited by 56
Inactivating ARID1A Tumor Suppressor Enhances TERT Transcription and Maintains Telomere Length in Cancer Cells
Rahmanto, Y. S., Jung, J.-G., Wu, R., Kobayashi, Y., Heaphy, C. M., Meeker, A. K., Wang, T., & Shih, I. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.707612 · Cited by 56
Self-citation
ARID1A deficiency and immune checkpoint blockade therapy: From mechanisms to clinical application
Hu, G., Tu, W., Liu, Y., Peng, G., & Yang, L. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.01.001 · Cited by 52
Self-citation
Translational genomics of ovarian clear cell carcinoma
Khalique, S., Lord, C. J., Banerjee, S. N., & Natrajan, R. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.10.025 · Cited by 51
Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma
O’Malley, D. M., Oza, A. M., Lorusso, D., Aghajanian, C. A., Oaknin, A., Dean, A. P., Colombo, N., Weberpals, J. I., Clamp, A. R., Scambia, G., et al. (2022) · Gynecologic Oncology · doi:10.1016/j.ygyno.2022.08.021 · Cited by 51
Prognostic role of ARID1A negative expression in gastric cancer
Ashizawa, M., Saito, M., Min, A. K. T., Ujiie, D., Saito, K., Sato, T., Kikuchi, T., Okayama, H., Fujita, S., Endo, H., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-43293-5 · Cited by 51
Unraveling the genomic complexity of small cell lung cancer
Karachaliou, N., Sosa, A. E., & Rosell, R. (2016) · Translational Lung Cancer Research · doi:10.21037/tlcr.2016.07.02 · Cited by 50
The ARID1A-METTL3-m6A axis ensures effective RNase H1-mediated resolution of R-loops and genome stability
Zhang, J., Chen, F., Tang, M., Xu, W., Tian, Y., Liu, Z., Shu, Y., Yang, H., Zhu, Q., Lu, X., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.113779 · Cited by 51
Next‐generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistance
Ahn, D. H., Javle, M. M., Ahn, C. W., Jain, A., Mikhail, S., Noonan, A. M., Wu, C. S.-Y., Shroff, R. T., Chen, J. L., & Bekaii‐Saab, T. (2016) · Cancer · doi:10.1002/cncr.30247 · Cited by 49
Loss of ARID1A expression is associated with poor prognosis in patients with gastric cancer
Zhu, Y. P., Li, S., Wu, J., Yang, M., Cheng, X. F., Wu, N.-N., Ye, X.-B., Cai, J., Wang, L., Shen, Q., et al. (2018) · Human Pathology · doi:10.1016/j.humpath.2018.04.003 · Cited by 49
Genome-wide CRISPR screens using isogenic cells reveal vulnerabilities conferred by loss of tumor suppressors
Feng, X., Tang, M., Dede, M., Su, D., Pei, G., Jiang, D., Wang, C., Chen, Z., Li, M., Nie, L., et al. (2022) · Science Advances · doi:10.1126/sciadv.abm6638 · Cited by 44
Predicting synthetic lethal interactions using conserved patterns in protein interaction networks
Benstead-Hume, G., Chen, X., Hopkins, S. R., Lane, K. A., Downs, J. A., & Pearl, F. M. G. (2019) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1006888 · Cited by 50
SWI/SNF Complexes in Ovarian Cancer: Mechanistic Insights and Therapeutic Implications
Fukumoto, T., Magno, E., & Zhang, R. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0368 · Cited by 47
Treatment Strategies for ARID1A-Deficient Ovarian Clear Cell Carcinoma
Takahashi, K., Takenaka, M., Okamoto, A., Bowtell, D. D. L., & Kohno, T. (2021) · Cancers · doi:10.3390/cancers13081769 · Cited by 47
Sophisticated Conversations between Chromatin and Chromatin Remodelers, and Dissonances in Cancer
Clapier, C. R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115578 · Cited by 46
A Review of the Clinical Characteristics and Novel Molecular Subtypes of Endometrioid Ovarian Cancer
Chen, S., Li, Y., Qian, L., Deng, S., Liu, L., Xiao, W., & Zhou, Y. Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.668151 · Cited by 47
Targeting the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Colorectal Cancer
Catalano, F., Borea, R., Puglisi, S., Boutros, A., Gandini, A., Cremante, M., Martelli, V., Sciallero, S., & Puccini, A. (2022) · Cancers · doi:10.3390/cancers14061388 · Cited by 44
Targeting USP9X–AMPK Axis in ARID1A-Deficient Hepatocellular Carcinoma
Zhang, F.-K., Ni, Q., Wang, K., Cao, H., Guan, D., Zhang, E., Ma, N., Wang, Y., Zheng, Q., Xu, S., et al. (2022) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2022.03.009 · Cited by 46
Loss of ARID1A expression predicts poor survival prognosis in gastric cancer: a systematic meta-analysis from 14 studies
Yang, L., Wei, S., Zhao, R., Wu, Y., Qiu, H., & Xiong, H. (2016) · Scientific Reports · doi:10.1038/srep28919 · Cited by 48
Self-citation
Combined treatment with PI3K inhibitor BKM120 and PARP inhibitor olaparib is effective in inhibiting the gastric cancer cells with ARID1A deficiency
Yang, L., Yang, G., Ding, Y., Huang, Y., Liu, S., Zhou, L., Wei, W., Wang, J., & Hu, G. (2018) · Oncology Reports · doi:10.3892/or.2018.6445 · Cited by 45
Self-citation
Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options
Personeni, N., Lleò, A., Pressiani, T., Colapietro, F., Openshaw, M. R., Stavraka, C., Pouptsis, A., Pinato, D. J., & Rimassa, L. (2020) · Cancers · doi:10.3390/cancers12113370 · Cited by 45
Emerging role of SWI/SNF complex deficiency as a target of immune checkpoint blockade in human cancers
Zhou, M., Yuan, J., Deng, Y., Fan, X., & Shen, J. (2021) · Oncogenesis · doi:10.1038/s41389-020-00296-6 · Cited by 49
Self-citation
SWI/SNF complex gene variations are associated with a higher tumor mutational burden and a better response to immune checkpoint inhibitor treatment: a pan-cancer analysis of next-generation sequencing data corresponding to 4591 cases
Li, Y., Yang, X., Zhu, W., Xu, Y., Ma, J., He, C., & Wang, F. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02757-x · Cited by 44
Loss of ARID1A expression leads to sensitivity to ROS-inducing agent elesclomol in gynecologic cancer cells
Kwan, S.-Y., Cheng, X., Tsang, Y. T. M., Choi, J.-S., Kwan, S., Izaguirre, D. I., Kwan, H. S., Gershenson, D. M., & Wong, K. (2016) · Oncotarget · doi:10.18632/oncotarget.10921 · Cited by 43
A Quantitative Chemotherapy Genetic Interaction Map Reveals Factors Associated with PARP Inhibitor Resistance
Hu, H., Zhao, X., Kaushik, S., Robillard, L., Barthelet, A., Lin, K., Shah, K. N., Simmons, A. D., Raponi, M., Harding, T. C., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.093 · Cited by 42
Co-existing TP53 and ARID1A mutations promote aggressive endometrial tumorigenesis
Reske, J. J., Wilson, M. R., Holladay, J., Siwicki, R. A., Skalski, H. J., Harkins, S. K., Adams, M., Risinger, J. I., Hostetter, G. H., Lin, K. Y., et al. (2021) · PLoS Genetics · doi:10.1371/journal.pgen.1009986 · Cited by 45
Exploiting epigenetic vulnerabilities in solid tumors: Novel therapeutic opportunities in the treatment of SWI/SNF-defective cancers
Chabanon, R. M., Morel, D., & Postel-Vinay, S. C. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.09.018 · Cited by 44
ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer
Johnson, R. M., Qu, X., Lin, C.-F., Huw, L.-Y., Venkatanarayan, A., Sokol, E., Ou, F.-S., Ihuegbu, N., Zill, O. A., Kabbarah, O., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33172-5 · Cited by 42
Inhibition of PI3K/AKT Signaling Pathway Radiosensitizes Pancreatic Cancer Cells with ARID1A Deficiency in Vitro
Yang, L., Yang, G., Ding, Y., Dai, Y., Xu, S., Guo, Q., Xie, A., & Hu, G. (2018) · Journal of Cancer · doi:10.7150/jca.21306 · Cited by 42
Self-citation
Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer
Eoh, K. J., Kim, H. M., Lee, J., Kim, S., Kim, S. W., Kim, Y. T., & Nam, E. J. (2020) · BMC Cancer · doi:10.1186/s12885-020-6693-y · Cited by 42
Epigenetic modulators provide a path to understanding disease and therapeutic opportunityPreprint
Honer, M. A., Ferman, B. I., Gray, Z. H., Bondarenko, E. A., & Whetstine, J. R. (2024) · Genes & Development · doi:10.1101/gad.351444.123 · Cited by 44
Clinical significance of homologous recombination deficiency score testing in endometrial Cancer
Siedel, J., Ring, K. L., Hu, W., Dood, R. L., Wang, Y., Baggerly, K., Darcy, K. M., Conrads, T. P., Gallagher, S., Tshiaba, P., et al. (2021) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.12.010 · Cited by 41
ARID1A mutations in lung cancer: biology, prognostic role, and therapeutic implications
Jin, F., Yang, Z., Shao, J., Tao, J., Reißfelder, C., Loges, S., Zhu, L., & Schölch, S. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.04.005 · Cited by 39
R-loops’ m6A modification and its roles in cancers
Qiu, Y., Man, C., Zhu, L., Zhang, S., Wang, X., Gong, D., & Fan, Y. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02148-y · Cited by 39
Targeting homologous repair deficiency in breast and ovarian cancers: Biological pathways, preclinical and clinical data
Chartron, E., Theillet, C. G., Guiu, S., & Jacot, W. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.10.012 · Cited by 40
Selective sensitivity of EZH2 inhibitors based on synthetic lethality in ARID1A-deficient gastric cancer
Yamada, L., Saito, M., Min, A. K. T., Saito, K., Ashizawa, M., Kase, K., Nakajima, S., Onozawa, H., Okayama, H., Endo, H., et al. (2020) · Gastric Cancer · doi:10.1007/s10120-020-01094-0 · Cited by 39
Different SWI/SNF complexes coordinately promote R-loop- and RAD52-dependent transcription-coupled homologous recombination
Davó-Martínez, C., Helfricht, A., Ribeiro-Silva, C., Raams, A., Tresini, M., Uruci, S., van Cappellen, W. A., Taneja, N., Demmers, J., Pines, A., et al. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad609 · Cited by 38
Targeting Arachidonic Acid Metabolism Enhances Immunotherapy Efficacy in ARID1A-Deficient Colorectal Cancer
Cui, L., Liu, R., Han, S., Zhang, C., Wang, B., Ruan, Y., Yu, X., Li, Y., Yao, Y., Guan, X., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-24-1611 · Cited by 43
Emerging therapeutic modalities of PARP inhibitors in breast cancer
Wang, X., Shi, Y., Huang, D., & Guan, X. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.05.014 · Cited by 38
Next-generation sequencing reveals heterogeneous genetic alterations in key signaling pathways of mismatch repair deficient colorectal carcinomas
Wang, J., Li, R., He, Y., Yi, Y., Wu, H., & Liang, Z. (2020) · Modern Pathology · doi:10.1038/s41379-020-0612-2 · Cited by 37
Monitoring of Dynamic Changes and Clonal Evolution in Circulating Tumor DNA From Patients With IDH -Mutated Cholangiocarcinoma Treated With Isocitrate Dehydrogenase Inhibitors
Lapin, M., Huang, H. J., Chagani, S., Javle, M. M., Shroff, R. T., Pant, S., Gouda, M. A., Raina, A., Madwani, K., Holley, V. R., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00197 · Cited by 38
PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?
Ricci, A. D., Rizzo, A., Bonucci, C., Tober, N., Palloni, A., Mollica, V., Maggio, I., Deserti, M., Tavolari, S., & Brandi, G. (2020) · Medicines · doi:10.3390/medicines7090054 · Cited by 37
Genetic alterations and their therapeutic implications in epithelial ovarian cancer
Lapke, N., Chen, C., Chang, T., Chao, A., Lu, Y., Lai, C., Tan, K. T., Chen, H., Lu, H., & Chen, S. (2021) · BMC Cancer · doi:10.1186/s12885-021-08233-5 · Cited by 41
Somatic ARID1A mutation stratifies patients with gastric cancer to PD-1 blockade and adjuvant chemotherapy
Gu, Y., Zhang, P., Wang, J., Lin, C., Liu, H., Li, H., He, H., Li, R., Zhang, H., & Zhang, W. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03326-x · Cited by 37
Self-citation
Treatment response and tumor evolution: lessons from an extended series of multianalyte liquid biopsies in a metastatic breast cancer patientPreprint
Welter, L. M., Xu, L., McKinley, D., Dago, A. E., Prabakar, R. K., Restrepo-Vassalli, S., Xu, K., Rodrı́guez-Lee, M., Kolatkar, A. R., Nevarez, R., et al. (2020) · Molecular Case Studies · doi:10.1101/mcs.a005819 · Cited by 37
ARID1A mutations in cancer development: mechanism and therapy
Zhang, X., Zhang, Y., Zhao, J., Wu, Y., Zhang, N., & Shen, W. (2023) · Carcinogenesis · doi:10.1093/carcin/bgad011 · Cited by 40
Targeting ARID1A-mutant colorectal cancer: depletion of ARID1B increases radiosensitivity and modulates DNA damage response
Niedermaier, B., Sak, A., Zernickel, E., Xu, S., Groneberg, M., & Stuschke, M. (2019) · Scientific Reports · doi:10.1038/s41598-019-54757-z · Cited by 36
Therapeutic Targets and Opportunities in Endometrial Cancer: Update on Endocrine Therapy and Nonimmunotherapy Targeted Options
MacKay, H. J., Freixinos, V. R., & Fleming, G. F. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280495 · Cited by 38
Somatic mutation of the cohesin complex subunit confers therapeutic vulnerabilities in cancer
Liu, Y., Xu, H., der Jeught, K. V., Li, Y., Liu, S., Zhang, L., Fang, Y., Zhang, X., Radovich, M., Schneider, B. P., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci98727 · Cited by 38
Retracted
Effect and biomarker of immune checkpoint blockade therapy for ARID1A deficiency cancers
Wang, L., Qu, J., Zhou, N., Hou, H., Jiang, M., & Zhang, X. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110626 · Cited by 35
Patient-derived xenograft models capture genomic heterogeneity in endometrial cancer
Bonazzi, V., Kondrashova, O., Smith, D. S., Nones, K., Sengal, A. T., Ju, R. J., Packer, L., Koufariotis, L. T., Kazakoff, S. H., Davidson, A. L., et al. (2022) · Genome Medicine · doi:10.1186/s13073-021-00990-z · Cited by 34
The SWI/SNF ATPase BRG1 stimulates DNA end resection and homologous recombination by reducing nucleosome density at DNA double strand breaks and by promoting the recruitment of the CtIP nuclease
Hays, E., Nettleton, E., Carter, C., Morales, M., Vo, L. A., Passo, M., & Vélez-Cruz, R. (2020) · Cell Cycle · doi:10.1080/15384101.2020.1831256 · Cited by 36
Comprehensive molecular phenotyping of ARID1A -deficient gastric cancer reveals pervasive epigenomic reprogramming and therapeutic opportunities
Xu, C., Huang, K. K., Law, J. H., Chua, J. S., Sheng, T., Flores, N. M., Pizzi, M. P., Okabe, A., Tan, A. L. K., Zhu, F., et al. (2023) · Gut · doi:10.1136/gutjnl-2022-328332 · Cited by 34
Perspectives on cancer therapy—synthetic lethal precision medicine strategies, molecular mechanisms, therapeutic targets and current technical challenges
Peng, S., Long, M., Chen, Q.-S., Yin, Z., Zeng, C., Zhang, W., Wen, Q., Zhang, X., Ke, W., & Wu, Y. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02418-8 · Cited by 38
Self-citation
ARID1A and CEBPα cooperatively inhibit UCA1 transcription in breast cancer
Guo, X., Zhang, Y., Mayakonda, A., Madan, V., Ding, L., Lin, L.-H., Zia, S., Gery, S., Tyner, J. W., Zhou, W., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0371-4 · Cited by 33
The role of the SWI/SNF chromatin remodeling complex in pancreatic ductal adenocarcinoma
Tsuda, M., Fukuda, A., Kawai, M., Araki, O., & Seno, H. (2020) · Cancer Science · doi:10.1111/cas.14768 · Cited by 36
Emerging role of precision medicine in biliary tract cancers
Bogenberger, J. M., DeLeon, T., Arora, M., Ahn, D. H., & Borad, M. J. (2018) · npj Precision Oncology · doi:10.1038/s41698-018-0064-z · Cited by 32
Genetic Mutations Underlying Phenotypic Plasticity in Basosquamous Carcinoma
Chiang, A., Tan, C. Z., Kuonen, F., Hodgkinson, L. M., Chiang, F., Cho, R. J., South, A. P., Tang, J. Y., Chang, A. L. S., Rieger, K. E., et al. (2019) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2019.03.1163 · Cited by 32
Widely metastatic glioblastoma with BRCA1 and ARID1A mutations: a case report
Umphlett, M., Shea, S., Tomé-García, J., Zhang, Y., Hormigo, A., Fowkes, M. E., Tsankova, N. M., & Yong, R. L. M. (2020) · BMC Cancer · doi:10.1186/s12885-020-6540-1 · Cited by 32
Modulation of STAT3 Signaling, Cell Redox Defenses and Cell Cycle Checkpoints by β-Caryophyllene in Cholangiocarcinoma Cells: Possible Mechanisms Accounting for Doxorubicin Chemosensitization and Chemoprevention
Sotto, A. D., Giacomo, S. D., Rubini, E., Macone, A., Gullì, M., Mammola, C. L., Eufemi, M., Mancinelli, R., & Mazzanti, G. (2020) · Cells · doi:10.3390/cells9040858 · Cited by 32
Pathway-Enriched Gene Signature Associated with 53BP1 Response to PARP Inhibition in Triple-Negative Breast Cancer
Hassan, S. N., Esch, A. M., Liby, T. A., Gray, J. W., & Heiser, L. M. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0170 · Cited by 31
Combination of talaporfin photodynamic therapy and Poly (ADP-Ribose) polymerase (PARP) inhibitor in gastric cancer
Tanaka, M., Sasaki, M., Suzuki, T., Nishie, H., & Kataoka, H. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.12.073 · Cited by 32
Expression and significance of EBV, ARID1A and PIK3CA in gastric carcinoma
Zhou, H., Tan, S., Li, H., & Lin, X. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.9886 · Cited by 31
DNA damage repair and survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy
Ronchetti, L., Melucci, E., Nicola, F. D., Goeman, F., Casini, B., Sperati, F., Pallocca, M., Terrenato, I., Pizzuti, L., Vici, P., et al. (2017) · International Journal of Cancer · doi:10.1002/ijc.30668 · Cited by 30
The BAF chromatin remodeling complexes: structure, function, and synthetic lethalities
Varga, J., Kube, M., Luck, K., & Schick, S. (2021) · Biochemical Society Transactions · doi:10.1042/bst20190960 · Cited by 31
ARID1A Mutation in Metastatic Breast Cancer: A Potential Therapeutic Target
Cheng, X., Zhao, J., Dong, F., & Cao, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.759577 · Cited by 31
The Novel ATR Inhibitor M1774 Induces Replication Protein Overexpression and Broad Synergy with DNA-targeted Anticancer Drugs
Jo, U., Arakawa, Y., Zimmermann, A., Taniyama, D., Mizunuma, M., Jenkins, L. M. M., Maity, T. K., Kumar, S., Zenke, F. T., Takebe, N., et al. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0402 · Cited by 29
ARID1A Gene Driver Mutations in Lung Adenocarcinomas
Karachaliou, N., Bracht, J. W. P., & Rosell, R. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.07.099 · Cited by 29
Synthetic lethality: A promising therapeutic strategy for hepatocellular carcinoma
Tang, L., Chen, R., & Xu, X. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.02.016 · Cited by 30
DNA Methylation Profiles of Ovarian Clear Cell Carcinoma
Cunningham, J. M., Winham, S. J., Wang, C., Weiglt, B., Fu, Z., Armasu, S. M., McCauley, B. M., Brand, A. H., Chiew, Y.-E., Elishaev, E., et al. (2021) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-21-0677 · Cited by 28
C5aR1 inhibition reprograms tumor associated macrophages and reverses PARP inhibitor resistance in breast cancer
Li, X., Poire, A., Jeong, K. J., Zhang, D., Ozmen, T. Y., Chen, G., Sun, C., & Mills, G. B. (2024) · Nature Communications · doi:10.1038/s41467-024-48637-y · Cited by 31
Self-citation
Actionable co-alterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway
Heeke, A. L., Xiu, J., Elliott, A., Korn, W. M., Lynce, F. C., Pohlmann, P. R., Isaacs, C. J., Swain, S. M., Vidal, G. A., Schwartzberg, L. S., et al. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05849-2 · Cited by 28
BRG1, INI1, and ARID1B Deficiency in Endometrial Carcinoma
Kihara, A., Amano, Y., Matsubara, D., Fukushima, N., Fujiwara, H., & Niki, T. (2020) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001581 · Cited by 28
Critical DNA damaging pathways in tumorigenesis
Kloeber, J. A., & Lou, Z. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.04.012 · Cited by 30
Genetic Characterization of Cancer of Unknown Primary Using Liquid Biopsy Approaches
Laprovitera, N., Salamon, I., Gelsomino, F., Porcellini, E., Riefolo, M., Garonzi, M., Tononi, P., Valente, S., Sabbioni, S., Fontana, F., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.666156 · Cited by 28
A novel human endometrial epithelial cell line for modeling gynecological diseases and for drug screening
Park, Y., Jung, J.-G., Yu, Z.-C., Asaka, R., Shen, W., Wang, Y., Jung, W., Tomaszewski, A., Shimberg, G., Chen, Y., et al. (2021) · Laboratory Investigation · doi:10.1038/s41374-021-00624-3 · Cited by 28
Self-citation
(mis)-Targeting of SWI/SNF complex(es) in cancer
Reddy, D., Bhattacharya, S., & Workman, J. L. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10102-5 · Cited by 30
Next-Generation Sequencing Reveals Potential Predictive Biomarkers and Targets of Therapy for Urothelial Carcinoma in Situ of the Urinary Bladder
Garczyk, S., Ortiz‐Brüchle, N., Schneider, U., Lurje, I., Guricová, K., Gaisa, N. T., Lorsy, E., Lindemann-Docter, K., Heidenreich, A., & Knüchel, R. (2019) · American Journal Of Pathology · doi:10.1016/j.ajpath.2019.10.004 · Cited by 28
Mutual Regulation of ncRNAs and Chromatin Remodeling Complexes in Normal and Pathological Conditions
Bure, I. V., & Nemtsova, M. V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24097848 · Cited by 27
Diagnostic significance and prognostic role of the ARID1A gene in cancer outcomes (Review)
Pavlidou, E., & Balis, V. (2020) · World Academy of Sciences Journal · doi:10.3892/wasj.2020.37 · Cited by 28
Exploiting replicative stress in gynecological cancers as a therapeutic strategy
Ngoi, N. Y. L., Sundararajan, V., & Tan, D. S. P. (2020) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2020-001277 · Cited by 28
The Bromodomain Inhibitor PFI-3 Sensitizes Cancer Cells to DNA Damage by Targeting SWI/SNF
Lee, D., Lee, D.-Y., Hwang, Y.-S., Seo, H.-R., Lee, S.-A., & Kwon, J. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0289 · Cited by 28
SWI/SNF chromatin remodeling complex alterations in meningioma
Gill, C. M., Loewenstern, J., Rutland, J. W., Arib, H., Pain, M., Umphlett, M., Kinoshita, Y., McBride, R. B., Bederson, J. B., Donovan, M. J., et al. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03586-7 · Cited by 27
Mutation-Driven Signals of ARID1A and PI3K Pathways in Ovarian Carcinomas: Alteration Is An Opportunity
De, P. K. R., & Dey, N. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225732 · Cited by 28
Enhancement of E-cadherin expression and processing and driving of cancer cell metastasis by ARID1A deficiency
Wang, J., Yan, H., Zhang, Q., Liu, W., Jiang, Y.-H., Peng, G., Wu, F., Liu, X., Yang, P., & Liu, F. (2021) · Oncogene · doi:10.1038/s41388-021-01930-2 · Cited by 26
Self-citation
Molecular and Clinical Characterization of Patients With Metastatic Castration Resistant Prostate Cancer Achieving Deep Responses to Bipolar Androgen Therapy
Markowski, M. C., Kachhap, S. K., Marzo, A. M. D., Sena, L. A., Luo, J., Denmeade, S. R., & Antonarakis, E. S. (2021) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2021.08.001 · Cited by 27
The Emerging Role of Chromatin Remodeling Complexes in Ovarian Cancer
Vaicekauskaitė, I., Sabaliauskaitė, R., Lazutka, J. R., & Jarmalaitė, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213670 · Cited by 26
Efficacy of glutathione inhibitors for the treatment of ARID1A-deficient diffuse-type gastric cancers
Sasaki, M., Chiwaki, F., Kuroda, T., Komatsu, M., Matsusaki, K., Kohno, T., Sasaki, H., & Ogiwara, H. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.11.078 · Cited by 28
Effects of Tumor Mutational Burden and Gene Alterations Associated with Radiation Response on Outcomes of Postoperative Radiation Therapy in Non-Small Cell Lung Cancer
Shaverdian, N., Shepherd, A. F., Li, X., Offin, M. D., Lengel, H. B., Gelblum, D. Y., Wu, A. J.-C., Simone, C. B., Rimner, A., Jones, D. R., et al. (2022) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2022.02.014 · Cited by 25
Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation
Serra-Camprubí, Q., Verdaguer, H., Oliveros, W., Lupión-Garcia, N., Llop‐Guevara, A., Molina, C., Vila-Casadesús, M., Turpin, A., Neuzillet, C., Frigola, J., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2551 · Cited by 26
SWI/SNF Complex-Deficient Undifferentiated Carcinoma of the Pancreas: Clinicopathologic and Genomic Analysis
Yavas, A., Özcan, K., Adsay, V. N., Balcı, S., Tarcan, Z. C., Hechtman, J. F., Luchini, C., Scarpa, A., Lawlor, R. T., Mafficini, A., et al. (2024) · Modern Pathology · doi:10.1016/j.modpat.2024.100585 · Cited by 24
Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials
MacKay, H. J., Levine, D. A., Bae-Jump, V. L., Bell, D. W., McAlpine, J. N., Santin, A. D., Fleming, G. F., Mutch, D. G., Nephew, K. P., Wentzensen, N., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19961 · Cited by 25
Targeting DNA Damage Response Pathway in Ovarian Clear Cell Carcinoma
Wong, O. G., Li, J., & Cheung, A. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.666815 · Cited by 24
Temozolomide Sensitizes ARID1A -Mutated Cancers to PARP Inhibitors
Yu, Z.-C., Li, T., Tully, E., Huang, P., Chen, C., Oberdoerffer, P., Gaillard, S. L., Shih, I., & Wang, T. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-3646 · Cited by 27
Self-citation
From clinical management to personalized medicine: novel therapeutic approaches for ovarian clear cell cancer
Liu, Z., Jing, C., & Kong, F. (2024) · Journal of Ovarian Research · doi:10.1186/s13048-024-01359-7 · Cited by 26
Histone Deacetylase Inhibition Has Targeted Clinical Benefit in ARID1A -Mutated Advanced Urothelial Carcinoma
Gupta, S. V., Albertson, D. J., Parnell, T. J., Butterfield, A., Weston, A., Pappas, L. M., Dalley, B. K., O’Shea, J. M., Lowrance, W. T., Cairns, B. R., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0957 · Cited by 24
Therapeutic Actionability of Circulating Cell-Free DNA Alterations in Carcinoma of Unknown Primary
Kato, S., Weipert, C. M., Gumas, S., Okamura, R., Lee, S., Sicklick, J. K., Saam, J. R., & Kurzrock, R. (2021) · JCO Precision Oncology · doi:10.1200/po.21.00011 · Cited by 24

Authors: Shen, J., Peng, Y., Wei, L., Zhang, W., Yang, L., Lan, L., Kapoor, P., Ju, Z., Mo, Q., Shih, I.-M., Uray, I. P., Wu, X., Brown, P. H., Shen, X., Mills, G. B., & Peng, G.
Affiliations: The University of Texas MD Anderson Cancer Center (US)
University of Pittsburgh (US)
Baylor College of Medicine (US)
Johns Hopkins University (US)
1Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Corresponding author: Peng, Guang
ORCID: Shen, Jianfeng
Peng, Yang
Zhang, Wei
Yang, Lin
Lan, Li
Ju, Zhenlin
Mo, Qianxing
Shih, Ie-Ming
Wu, Xiangwei
Brown, Powel H.
Mills, Gordon B.
Peng, Guang
Venue: Cancer Discovery
Publisher: American Association for Cancer Research (AACR)
Published: 2015-07-01
Volume: 5
Issue: 7
Pages: 752-767
ISSN: 2159-8274 (ISSN-L)
2159-8290
DOI: 10.1158/2159-8290.cd-14-0849
PMC: PMC4497871
OpenAlex: W2123454509
Cited by: 522
References: 61
Citations by year: 2026: 33 · 2025: 53 · 2024: 59 · 2023: 56 · 2022: 53 · 2021: 71 · 2020: 62 · 2019: 43 · 2018: 36 · 2017: 28 · 2016: 24 · 2015: 3
FWCI: 13.16
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Cancer Discovery (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
University of Debrecen Electronic Archive (University of Debrecen) (submittedVersion)
eScholarship (California Digital Library) (submittedVersion)
Funders: National Cancer Institute (CA 016672, P50CA098258, P50-CA83639, R00CA149186, K99CA149186, P50CA083639, P30CA016672, R01CA181663)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
Keywords: ARID1A, SWI/SNF complex, DNA damage checkpoint, PARP inhibitors, ATR kinase, DNA double-strand breaks, tumor suppressor, drug sensitivity
MeSH terms: Poly(ADP-ribose) Polymerase Inhibitors, Animals, Breast Neoplasms, DNA Damage, DNA-Binding Proteins, Female, Humans, Lung Neoplasms, Male, Nuclear Proteins, Transcription Factors, Xenograft Model Antitumor Assays, HCT116 Cells, Cell Line, Tumor, Mice, DNA Breaks, Double-Stranded, Ataxia Telangiectasia Mutated Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks